[Adults] FORBES Article Published Recently Prominently Praises Nuvilex (NVLX)

[Biotech Penny Stock Information]

Nuvilex Inc. (NVLX)

FORBES Editorial Issued Recently Notably Features Nuvilex (NVLX)

As released in FORBES in their September 23rd issue in a all-inclusive
article examining the pace at which large pharmaceutical companies such as
Amgen, Celgene, Roche/Genentech, and Eli Lilly are developing solutions to
treat liver, kidney, breast and pancreatic cancers, "If Nuvilex were to
reprise its phase II results in a phase III trial, the firm's technology
"would likely be the oncology treatment story of the year," says analyst
Rob Goldman of Goldman Small Cap Research in FORBES this week.  FORBES
continued to report, "The current gold standard is Eli Lilly's (LLY) Gemzar
[http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=25&F=T],
which has proven a one-year survival rate of 18% and a average overall
survival time of 6.7 months."  Goldman Small Cap Research says "In its
phase II clinical studies, the drug ifosfamide encapsulated through the
Nuvilex technology amplified the survival time. The average survival rate
almost doubled and the one-year survival  time doubled compared with the
historical data for Gemzar."



FORBES, INVESTING - September 23, 2013

Biotechs Are Back In Favor Amongst Excess Of Positive Developments

The FDA also green lit Celgene
[http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=26&F=T]
CELG +0.9%
[http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=27&F=Ts
(CELG) Abraxane for pancreatic cancer, for which there are scarce effectual
treatment and survival time are significantly low. "The current gold
standard is Eli Lilly's (LLY) Gemzar
[http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=25&F=T],
which has established a one-year survival rate of 18% and a average overall
survival rate of 6.7 months, says biotech analyst Robert Goldman of Goldman
Small-Cap Research.    "This low survival time has encouraged a newer
biopharmaceutical company called Nuvilex (NVLX) to hunt for means to make
existing drugs substantially more effective, with lower dosage and lesser
side effects."

"With Nuvilex's technology, live cells that express high amounts of the
enzyme CYP 281 will be encapsulated in cellulose-based, pin-head sized
capsules implanted close to the pancreas, and near to the tumor itself,"
says Goldman. A widely dispersed anti-cancer drug Ifosfamide is then given
intravenously, at low doses, to the patient receiving the encapsulated
cells.

Goldman declares that in their phase II clinical studies, the drug
ifosfamide encapsulated via the Nuvilex technology enhanced the survival
time. "The average survival time almost doubled and the one-year survival
time doubled compared with the historical data for Gemzar," says Goldman.
"If Nuvilex were to echo its phase II results in a phase III trial, the
company's technology "would likely be the oncology treatment story of the
year," says Goldman.

To see the full article in FORBES, please go to
http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=24&F=T

10000 N Central Expressway, Suite 400, Dallas, TX 75231 United States

 The use of research materials circulated by the auth.or is done at your
own risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this report.

 Discontinue me from this newsletter
http://notif.all-about-battery.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=4923


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20131003/228ed701/attachment.html>